公开(公告)号：US12060357B2

公开(公告)日：2024-08-13

申请号：US17657515

申请日：2022-03-31

申请人： Merck Sharp & Dohme LLC

发明人： Matthew A. Larsen ,  Amjad Ali ,  Jared Cumming ,  Duane DeMong ,  Qiaolin Deng ,  Thomas H. Graham ,  Elisabeth Hennessy ,  Andrew J. Hoover ,  Ping Liu ,  Kun Liu ,  Umar Faruk Mansoor ,  Jianping Pan ,  Christopher W. Plummer ,  Aaron Sather ,  Uma Swaminathan ,  Huijun Wang ,  Yonglian Zhang

IPC分类号： C07D487/04 ,  C07K16/28

CPC分类号： C07D487/04 ,  C07K16/2818

摘要： In its many embodiments, the present invention provides certain 9-substituted amino triazolo quinazoline compounds of the structural Formula (I):




and pharmaceutically acceptable salts thereof, wherein, ring A, R1 and R2 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

公开(公告)号：US20240076297A1

公开(公告)日：2024-03-07

申请号：US18015364

申请日：2021-07-22

申请人： Merck Sharp & Dohme LLC

发明人： Amjad Ali ,  Jared N. Cumming ,  Manuel De Lera Ruiz ,  Duane DeMong ,  Thomas H. Graham ,  Elisabeth T. Hennessy ,  Joseph M. Kelly ,  Rongze Kuang ,  Michael Man-Chu Lo ,  Umar Faruk Mansoor ,  Jesus Moreno ,  Uma Swaminathan ,  Heping Wu ,  Yingchun Ye ,  Younong Yu

IPC分类号： C07D487/04 ,  A61K45/06 ,  C07D519/00 ,  C07K16/28

CPC分类号： C07D487/04 ,  A61K45/06 ,  C07D519/00 ,  C07K16/2818

摘要： The present invention provides compounds of the structural Formula (I), and pharmaceutically acceptable salts thereof, wherein, are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

公开(公告)号：US20230257371A1

公开(公告)日：2023-08-17

申请号：US18015671

申请日：2021-07-15

申请人： Michael ALTMAN ,  David A. CANDITO ,  Alec H. CHRISTIAN ,  Ornella DI PIETRO ,  Min LU ,  Umar Faruk MANSOOR ,  Katrina Marie MENNIE ,  Andrew J. MUSACCHIO ,  Anandan PALANI ,  Michael H. REUTERSHAN ,  David Matthew SHAW ,  MERCK SHARP & DOHME LLC ,  MSD R&D INNOVATION CENTRE LIMITED

发明人： Michael D. Altman ,  David A. Canditio ,  Alec H. Christian ,  Ornella Di Pietro ,  Min Lu ,  Umar Faruk Mansoor ,  Katrina Marie Mennie ,  Andrew J. Musacchio ,  Anandan Palani ,  Michael H. Reutershan ,  David Matthew Shaw ,  Ping Lui ,  Stephen St-Gallay

IPC分类号： C07D413/04 ,  C07D403/06 ,  C07D265/36 ,  C07D401/06 ,  C07D491/048 ,  C07D471/04 ,  C07D209/96 ,  C07D487/04 ,  C07D307/94

CPC分类号： C07D413/04 ,  C07D403/06 ,  C07D265/36 ,  C07D401/06 ,  C07D491/048 ,  C07D471/04 ,  C07D209/96 ,  C07D487/04 ,  C07D307/94

摘要： The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.